Literature DB >> 26891076

Hypoxia/ischemia promotes CXCL10 expression in cardiac microvascular endothelial cells by NFkB activation.

Jing-Bo Xia1, Guang-Hui Liu1, Zhuo-Ying Chen1, Cheng-Zhou Mao1, Deng-Cheng Zhou1, Hai-Yan Wu1, Kyu-Sang Park2, Hui Zhao3, Soo-Ki Kim4, Dong-Qing Cai5, Xu-Feng Qi6.   

Abstract

CXCL10, the chemokine with potent chemotactic activity on immune cells and other non-immune cells expressing its receptor CXCR3, has been demonstrated to involve in myocardial infarction, which was resulted from hypoxia/ischemia. The cardiac microvascular endothelial cells (CMECs) are the first cell type which is implicated by hypoxia/ischemia. However, the potential molecular mechanism by which hypoxia/ischemia regulates the expression of CXCL10 in CMECs remains unclear. In the present study, the expression of CXCL10 was firstly examined by real-time PCR and ELISA analysis. Several potential binding sites (BS) for transcription factors including NF-kappaB (NFkB), HIF1 alpha (HIF1α) and FoxO3a were identified in the promoter region of CXCL10 gene from -2000 bp to -1 bp using bioinformatics software. Luciferase reporter gene vectors for CXCL10 promoter and for activation of above transcription factors were constructed. The activation of NFkB, hypoxia-inducible transcription factor-1 alpha (HIF-1α) and FoxO3a was also analyzed by Western blotting. It was shown that the production of CXCL10 in CMECs was significantly increased by hypoxia/ischemia treatment, in parallel with the activation of CXCL10 promoter examined by reporter gene vector system. Furthermore, transcription factors including NFkB, HIF1α and FoxO3a were activated by hypoxia/ischemia in CMECs. However, over-expression of NFkB, but not that of HIF1α or FoxO3a, significantly promoted the activation of CXCL10 promoter reporter gene. These findings indicated that CXCL10 production in CMECs was significantly increased by hypoxia/ischemia, at least in part, through activation of NFkB pathway and subsequently binding to CXCL10 promoter, finally promoted the transcription of CXCL10 gene.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CMECs; CXCL10; Expression; Hypoxia/ischemia; NFkB

Mesh:

Substances:

Year:  2016        PMID: 26891076     DOI: 10.1016/j.cyto.2016.02.007

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  17 in total

Review 1.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

2.  Inhibition of C-X-C motif chemokine 10 reduces graft loss mediated by memory CD8+ T cells in a rat cardiac re-transplant model.

Authors:  Jiacheng Xu; Teng Ma; Guorong Deng; Jiawei Zhuang; Cheng Li; Shaohu Wang; Chen Dai; Xiaobiao Zhou; Zhonggui Shan; Zhongquan Qi
Journal:  Exp Ther Med       Date:  2017-12-01       Impact factor: 2.447

3.  Exosomal miR-27b-3p Derived from Hypoxic Cardiac Microvascular Endothelial Cells Alleviates Rat Myocardial Ischemia/Reperfusion Injury through Inhibiting Oxidative Stress-Induced Pyroptosis via Foxo1/GSDMD Signaling.

Authors:  Baojian Zhang; Chao Sun; Yaozhong Liu; Fan Bai; Tao Tu; Qiming Liu
Journal:  Oxid Med Cell Longev       Date:  2022-07-06       Impact factor: 7.310

4.  Acute Kidney Injury in Children after Hematopoietic Cell Transplantation Is Associated with Elevated Urine CXCL10 and CXCL9.

Authors:  Daniella Levy Erez; Michelle R Denburg; Simisola Afolayan; Sonata Jodele; Gregory Wallace; Stella M Davies; Alix E Seif; Nancy Bunin; Benjamin L Laskin; Kathleen E Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2020-03-09       Impact factor: 5.742

Review 5.  TAK1 signaling is a potential therapeutic target for pathological angiogenesis.

Authors:  Linxin Zhu; Suraj Lama; Jiang-Hui Wang; Guei-Sheung Liu; Leilei Tu; Gregory J Dusting
Journal:  Angiogenesis       Date:  2021-05-10       Impact factor: 10.658

Review 6.  The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart.

Authors:  Raffaele Altara; Ziad Mallat; George W Booz; Fouad A Zouein
Journal:  J Immunol Res       Date:  2016-10-03       Impact factor: 4.818

7.  Intense light-elicited upregulation of miR-21 facilitates glycolysis and cardioprotection through Per2-dependent mechanisms.

Authors:  Colleen Marie Bartman; Yoshimasa Oyama; Kelley Brodsky; Ludmila Khailova; Lori Walker; Michael Koeppen; Tobias Eckle
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

8.  Qiliqiangxin attenuates hypoxia-induced injury in primary rat cardiac microvascular endothelial cells via promoting HIF-1α-dependent glycolysis.

Authors:  Yanyan Wang; Xueting Han; Mingqiang Fu; Jingfeng Wang; Yu Song; Yuan Liu; Jingjing Zhang; Jingmin Zhou; Junbo Ge
Journal:  J Cell Mol Med       Date:  2018-03-04       Impact factor: 5.310

9.  Down-Regulation of microRNA-30d Alleviates Intervertebral Disc Degeneration Through the Promotion of FOXO3 and Suppression of CXCL10.

Authors:  Peng Xia; Xu Gao; Fang Li; Liwei Shao; Yifu Sun
Journal:  Calcif Tissue Int       Date:  2020-10-28       Impact factor: 4.333

10.  Analysis of region specific gene expression patterns in the heart and systemic responses after experimental myocardial ischemia.

Authors:  Matthias Zimmermann; Lucian Beer; Robert Ullrich; Dominika Lukovic; Elisabeth Simader; Denise Traxler; Tanja Wagner; Lucas Nemec; Lukas Altenburger; Andreas Zuckermann; Mariann Gyöngyösi; Hendrik Jan Ankersmit; Michael Mildner
Journal:  Oncotarget       Date:  2017-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.